#Raw Materials
Applied DNA CEO discusses relevance of DNA-based cotton traceability as enabler of ethical and responsible textile manufacturing on BBC Business Daily
CertainT® for Cotton Traceability
CertainT, Applied DNA’s traceability platform, provides an approach to authenticate goods within large and complex supply chains for materials such as cotton, and leather, home textiles and apparel, pharmaceuticals and nutraceuticals, personal care, cannabis, and other products. To date, CertainT has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.
CertainT begins by authenticating the fiber content in cotton to confirm its origin. The platform then employs a unique molecular identifier produced by the Company’s LinearDNA™ platform to mark cotton fibers in bulk. The cotton fiber is then tested for the presence of the identifier via the Company’s proprietary, portable readers as the cotton fiber travels throughout a global supply chain and is converted into yarn, fabric, and finished goods. The detection of the identifier confirms origin and authenticity; its absence can signal for blending with illicit cotton, including cotton potentially produced by means of forced labor. The CertainT logo signifies to consumers of cotton products that they can trust the products they are buying with said trust grounded in forensic, science-based authentication. Consumers can therefore be confident in the knowledge that Brands and their supply chains have taken the necessary steps to assure that the cotton product itself is authentic and sustainably and responsibly sourced from a known origin.
The episode is available at
https://www.bbc.co.uk/sounds/play/w3ct1jn9.
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company’s deep expertise in DNA.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
